Mandate

Vinge advises AcadeMedia in connection with the public offer from Providence

April 22, 2010

Vinge advises AcadeMedia AB (publ) ("AcadeMedia") in connection with the public offer from Providence for all outstanding shares in AcadeMedia, which was announced on 22 April 2010. Providence offers SEK 170 for each share in AcadeMedia and the total value of the offer amounts to SEK 2,050 million. Providence has received undertakings to accept the offer from some of the major shareholders in AcadeMedia, who together own shares corresponding to approximately 17.4 per cent of all outstanding shares and votes in AcadeMedia. The offer is recommended by the bid committee of AcadeMedia which has been appointed in connection with the offer.
 
AcadeMedia is the largest education company in Sweden. AcadeMedia currently has approximately 45,000 students and course attendants, in excess of 100 schools and around 2,500 employees with operations within the entire Swedish education area: pre-, compulsory-, and upper secondary schools and within adult education. The operations are conducted through independent schools and companies such as Vittra, NTI, Rytmus, IT-Gymnasiet, Ljud & Bildskolan and Mikael Elias Teoretiska Gymnasium. AcadeMedia is listed on NASDAQ OMX Stockholm, Small Cap.

Vinge's team consists of Göran Nyström and Dain Nevonen. Erik Sjöman and Jesper Schönbeck have advised in certain matters related to capital markets law.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026